NASDAQ
KZIA
Last Price
US $13.47
KEY FIGURES
MKT CAP
$21.8M
EPS
TTM
$-7.14
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
2138.10x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Kazia Therapeutics Ltd ADR cash flow to debt ratio of -3.35K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Kazia Therapeutics Ltd ADR's free cash flow has decreased 38.59% from $-9.58M last year to $-13.28M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Kazia Therapeutics Ltd ADR's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Kazia Therapeutics Ltd ADR's debt has increased relative to shareholder equity from -0.06 last year to 0.00 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Kazia Therapeutics Ltd ADR has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Kazia Therapeutics Ltd ADR earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Kazia Therapeutics Ltd ADR's profit margin has decreased (9.64K%) in the last year from -1.16K% to -113.00K%, signaling decreasing performance
Financial risk - Short term assets vs short term liabilities.
Kazia Therapeutics Ltd ADR's short-term liabilities of $14.05M exceed its short-term assets of $4.93M, signaling financial risk
Decreasing performance - ROA.
Kazia Therapeutics Ltd ADR's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Kazia Therapeutics Ltd ADR's return on equity of -116.86%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Kazia Therapeutics Ltd ADR's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Kazia Therapeutics Ltd ADR had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Kazia Therapeutics Ltd ADR has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Kazia Therapeutics Ltd ADR has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Kazia Therapeutics Ltd ADR's yearly earnings has increased -22.69% since last year from $-26.78M to $-20.70M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
Kazia Therapeutics Ltd ADR's yearly revenue has decreased -98.18% since last year from $2.31M to $42.00K, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -36.21% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Kazia Therapeutics Ltd ADR's 3-year revenue CAGR of 61.34% is positive, indicating growing revenue over the past 3 years
Decreasing performance - Revenue consistency.
Kazia Therapeutics Ltd ADR had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Kazia Therapeutics Ltd ADR had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Kazia Therapeutics Ltd ADR has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Kazia Therapeutics Ltd ADR has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Kazia Therapeutics Ltd ADR is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Kazia Therapeutics Ltd ADR has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Kazia Therapeutics Ltd ADR has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Kazia Therapeutics Ltd ADR has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Kazia Therapeutics Ltd ADR has a price-to-sales ratio of 2.14Kx, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-116.86%
Return on equity
ROIC: -36.21%
Valuation History
-1.9X
Price to Earnings
EV/EBITDA: 2.1X
Cash flow
Profit margin
-46.83%
(FY vs FY)
EBITDA Y/Y
-3.51%
(FY vs FY)
Cash flow Y/Y
-7.88%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $13.47
—
Default assumptions
EBITDA Multiple
Fair Value
Market $13.47
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.